146 related articles for article (PubMed ID: 37861685)
1. Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes.
Gordon ER; Kwinta BD; Schreidah CM; Fahmy LM; Adeuyan O; Queen D; Trager MH; Magro CM; Geskin LJ
Leuk Lymphoma; 2024 Jan; 65(1):48-54. PubMed ID: 37861685
[TBL] [Abstract][Full Text] [Related]
2. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
Brumfiel CM; Patel MH; DiCaudo DJ; Rosenthal AC; Pittelkow MR; Mangold AR
Leuk Lymphoma; 2021 Oct; 62(10):2554-2555. PubMed ID: 33974494
[No Abstract] [Full Text] [Related]
4. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous marginal zone lymphoproliferative disorder following COVID-19 vaccination.
Stephan C; Barone P; Kim J; Ma L
J Cutan Pathol; 2024 Mar; 51(3):193-197. PubMed ID: 38018231
[TBL] [Abstract][Full Text] [Related]
6. SATB1 Defines a Subtype of Cutaneous CD30
Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
[TBL] [Abstract][Full Text] [Related]
7. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
9. Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID-19 vaccination: A reactive lymphomatoid papulosis-like eruption and a bona fide lymphoma.
Bresler SC; Menge TD; Tejasvi T; Carty SA; Hristov AC
J Cutan Pathol; 2023 Mar; 50(3):213-219. PubMed ID: 36437812
[TBL] [Abstract][Full Text] [Related]
10. Acral lymphomatoid papulosis: Report of five cases, differential diagnosis, and review.
Machan S; Juárez Martín Á; Cullen Aravena D; Haro R; Pielasinski Ú; Fuertes L; Córdoba R; Santonja C; Rodríguez-Pinilla SM; Requena L
J Cutan Pathol; 2021 May; 48(5):650-658. PubMed ID: 33269496
[TBL] [Abstract][Full Text] [Related]
11. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease.
Magro CM; Olson LC; Fulmer CG
Ann Diagn Pathol; 2017 Oct; 30():52-58. PubMed ID: 28965629
[TBL] [Abstract][Full Text] [Related]
12. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
13. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
14. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
15. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
Schwartz Z; Bowe RB; Coleman M; Magro CM
Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
[TBL] [Abstract][Full Text] [Related]
16. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W; Kerl K; Mitteldorf C
Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
[TBL] [Abstract][Full Text] [Related]
18. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Pfaltz K; Vermeer MH; Cozzio A; Ortiz-Romero PL; Bagot M; Olsen E; Kim YH; Dummer R; Pimpinelli N; Whittaker S; Hodak E; Cerroni L; Berti E; Horwitz S; Prince HM; Guitart J; Estrach T; Sanches JA; Duvic M; Ranki A; Dreno B; Ostheeren-Michaelis S; Knobler R; Wood G; Willemze R
Blood; 2011 Oct; 118(15):4024-35. PubMed ID: 21841159
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
Vonderheid EC; Sajjadian A; Kadin ME
J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
